Posted by Michael Wonder on 19 Aug 2016
Post-market review of biological disease modifying anti-rheumatic drugs to treat severe chronic plaque psoriasis and of pulmonary arterial hypertension medicines
19 August 2016 - The public consultation process on the draft terms of reference for the two post-market reviews has closed.
Submissions commenting on the draft terms of reference have been published on the PBS website.
Examine the 3 submissions to the post-market review of medicines for psoriasis
